Edrecolomab (monoclonal antibody 17-1A)
Edrecolomab (monoclonal antibody 17-1A)
复制标题
DOI：
10.2165/00003495-199856040-00011
复制
发表时间：
1998-10-01
期刊：
影响因子：
11.5
通讯作者：
Spencer, CM
中科院分区：
文献类型：
--
作者：
Adkins, JC;Spencer, CM
依地莫单抗是一种小鼠源性单克隆IgG 2a抗体。它识别人肿瘤相关抗原CO 17 -1A，该抗原在多种肿瘤和正常上皮组织的细胞表面上表达，认为依地莫单抗通过激活一系列内源性细胞毒性机制破坏肿瘤细胞，包括抗体依赖性细胞介导的细胞毒性和可能的抗体依赖性补体介导的细胞毒性。依地莫单抗可通过诱导宿主抗独特型抗体应答间接诱导抗肿瘤活性。（初始剂量为500 mg，随后每隔4周输注4次100 mg）在切除Dukes 'C期结直肠癌和微小残留病变的患者中，eddlomab显著提高了生存率，降低了肿瘤复发率。作为单一疗法或与醚类抗炎药联合治疗晚期结肠直肠或胰腺炎的疗效有限。然而，在晚期乳腺癌患者中进行的一项小型I期研究的结果更有希望。在一项上市后监测研究中，与依地莫单抗相关的最常见不良事件为潮红/红斑和胃肠道症状，包括腹泻、腹痛、恶心和呕吐。由于依地莫单抗是鼠源性的，因此在接受该药物治疗的一些患者中发生了过敏反应。
Edrecolomab is a mouse-derived monoclonal IgG2a antibody. It recognises the human tumour-associated antigen CO17-1A which is expressed on the cell surface of a wide variety of tumours and normal epithelial tissue.Edrecolomab is thought to destroy tumour cells by activating an array of endogenous cytotoxic mechanisms, including antibody-dependent cell-mediated cytotoxicity and possibly antibody-dependent complement mediated cytotoxicity. Edrecolomab may induce antitumour activity indirectly by inducing a host anti-idiotypic antibody response.Adjuvant therapy with edrecolomab (500mg initial dose followed by four 100mg infusions administered at 4-weekly intervals) significantly improved survival and reduced the tumour recurrence rate in patients with resected Dukes' stage C colorectal cancer and minimal residual disease.Data from several small clinical trials suggest that edrecolomab given as monotherapy or in combination with Ether antineoplastic agents has limited efficacy in the treatment of advanced colorectal or pancreatic rumours. However, results from a small phase I study in patients with advanced breast cancer were more promising.Edrecolomab was generally well tolerated in clinical trials. In a postmarketing surveillance study, the most common adverse events associated with edrecolomab were flushing/erythema and gastrointestinal symptoms including diarrhoea, abdominal pain and nausea and vomiting. Because edrecolomab is of murine origin, anaphylactic reactions have developed in some patients treated with the drug.